Get the Stockscreener App
60.63
0.56%
0.34
Pre-market:
60.45
-0.18
-0.30%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $60.63, with a volume of 10.96M.
It is up +0.56% in the last 24 hours and down -0.23% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$60.29
Open:
$59.92
24h Volume:
10.96M
Relative Volume:
0.78
Market Cap:
$123.47B
Revenue:
$48.19B
Net Income/Loss:
$7.06B
P/E Ratio:
17.53
EPS:
3.4587
Net Cash Flow:
$12.85B
1W Performance:
-2.74%
1M Performance:
-0.23%
6M Performance:
+28.37%
1Y Performance:
-0.75%
1-Day Range:
$59.25
$60.64
1-Week Range:
$59.25
$62.59
52-Week Range:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
60.63 | 122.78B | 48.19B | 7.06B | 12.85B | 3.4587 |
|
LLY
Lilly Eli Co
|
1,008.39 | 884.36B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.59 | 579.34B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
227.45 | 406.87B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
162.79 | 305.53B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
194.95 | 301.19B | 58.80B | 10.24B | 8.98B | 3.2788 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol Myers Squibb (NYSE:BMY) Boosts Research Strengthening S&P 500 Index Momentum - Kalkine Media
Bristol Myers Squibb reports positive phase 3 trial results - Investing.com
Bristol's cancer treatment meets main goal in late-stage trial - AOL.com
Bristol's drug enhances survival rates in late-stage blood cancer trial - Reuters
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates - GlobeNewswire Inc.
New Bristol Myers pill delays myeloma progression in key late-stage trial - Stock Titan
Blair William & Co. IL Reduces Bristol Myers Squibb Stake - National Today
Oral Mucositis Market Set to Boom Through 2033 | Bristol-Myers Squibb • Pfizer Inc. • Novartis AG - openPR.com
Pitcairn Co. Sells 20,260 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
B. Metzler seel. Sohn & Co. AG Has $5.05 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers (BMY) Gains FDA Approval for Sotyktu in Psoriatic Arthritis Treatment - GuruFocus
Munich Reinsurance Co Stock Corp in Munich Takes $2.78 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Has $43.66 Million Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb's Sotyktu Approved for Psoriatic Arthritis Treatment - Intellectia AI
Bristol Myers Wins FDA Approval for Sotyktu for Psoriatic Arthritis - Benzinga
Bristol Myers wins FDA nod to expand Sotyktu label (BMY:NYSE) - Seeking Alpha
Painful psoriatic arthritis gets new oral option with FDA Sotyktu approval - Stock Titan
UBS raises Bristol-Myers Squibb stock price target on pipeline outlook - Investing.com
Why Bristol-Myers Squibb Remains a Top Healthcare Dividend Stock Pick - Tokenist
IFG Advisory LLC Acquires New Position in Bristol Myers Squibb Company - National Today
Edgar Lomax Co. VA Reduces Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb's Cancer Drug Meets Key Trial Goals - Intellectia AI
Is It Too Late To Consider Bristol Myers Squibb (BMY) After Recent Share Price Strength? - simplywall.st
Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline? - TradingView
Assessing Bristol Myers Squibb (BMY) Valuation After Recent Share Price Momentum And 2024 Results - simplywall.st
Bristol Myers Squibb Awaits FDA Verdict On Sotyktu In Psoriatic Arthritis - RTTNews
Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks - Finviz
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
How New Oncology Wins and a Fresh Dividend At Bristol Myers Squibb (BMY) Have Changed Its Investment Story - simplywall.st
Wealthedge Investment Advisors Boosts Bristol Myers Squibb Holdings - National Today
Bristol Myers Squibb declares $0.63 quarterly dividend - Investing.com
APG Asset Management Trims Bristol Myers Squibb Stake - National Today
Elo Mutual Pension Insurance Co Increases Bristol Myers Squibb Position - National Today
Bristol-Myers Squibb (BMY) Maintains Quarterly Dividend of $0.63/Share - GuruFocus
Bristol Myers Squibb at TD Cowen Conference: Strategic Growth Amid Challenges - Investing.com
BMY Gains 11.4% in a Month: Should You Buy, Sell or Hold the Stock? - TradingView
Evinova and Bristol Myers Squibb Collaborate to Advance AI-Driven Clinical Development - The Healthcare Technology Report.
Elo Mutual Pension Insurance Co Has $13.63 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
What Bristol-Myers Squibb (BMY)'s Triple-Negative Breast Cancer Phase III Survival Win Means For Shareholders - Yahoo Finance
Bristol-Myers Squibb Cancer Advances Test Valuation Gap For Investors - simplywall.st
Is Bristol Myers Squibb (BMY) Pricing Look Attractive After Recent Share Price Climb - Yahoo Finance
Intech Investment Management Reduces Stake in Bristol Myers Squibb - National Today
Bristol-Myers Campus Sale Suit Sent Back To NJ - Law360
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
US Bancorp DE Trims Bristol Myers Squibb Stake - National Today
Is Bristol-Myers Squibb Stock Underperforming the Nasdaq? - Barchart.com
Mitsubishi UFJ Asset Management Co. Ltd. Has $204.06 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
BMY Stock Price, Forecast & Analysis | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Bristol Myers Squibb (NYSE:BMY) Update Pharma Sector Developments - Kalkine Media
Bristol Myers Says New Breast Cancer Drug Shows Survival Benefit In Pretreated Patients - Benzinga
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
3.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):